RCCS San Raffaele Scientific Institute in Milan researchers have discovered that hematopoietic stem cells (HSCs) adapt their lineage commitment during gene therapy based on the underlying genetic ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session –– Tebapivat Phase 1 ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...

Vertex Pharmaceuticals beat Wall Street's third-quarter expectations, but the real story for Vertex stock is still to come, analysts said Tuesday.Please watch the video at Investors.com - How To Buy ...

Editas Medicine EDIT incurred a loss of 75 cents per share in the third quarter of 2024, narrower than the Zacks Consensus ...

Vertex is approaching two key PDUFA dates in January for new treatments in cystic fibrosis and pain respectively.

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of ...

StockNews.com assumed coverage on shares of bluebird bio (NASDAQ:BLUE – Free Report) in a report released on Saturday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

This case study is an example of how the MHRA is benefiting from patients providing their lived experience for the pre-authorisation stage of the ...